MLMarc J. Lajoie

Marc J. Lajoie

*This is an algorithmically generated author record based on publicly available information.

Marc J. Lajoie has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling

    by Howell F. Moffett, Brian D. Weitzner, Michelle M. Lissner, Thaddeus M. Davenport, Kevin G. Haworth, Erika T. Hayes, Robert A. Langan, Leah J. Tait, Willimark M. Obenza, Bradley Hammerson, et al.

    Cytokines mediate cell-cell communication to coordinate immune responses and hold clinical promise as immunotherapies 1–3 . While natural cytokines are exquisitely regulated by immune cells, engineered cytokines have not yet matched this sophisticated regulation, limiting clinical efficacy and safety 4,5 . IL-2 is an important cytokine involved in antitumor response, but its production is disrupted in the immune-suppressive tumor microenvironment. Here we designed a regulated IL-2 module, OUTSMART designed IL-2 (dIL-2), that functions robustly in solid tumors and reduces systemic activity that could trigger toxicity: we computationally redesigned IL-2 to have a novel topology that increases stability, preserves native IL-2Rβγ interfaces, ablates IL-2Rα binding, and delivers IL-2 signaling to CD8α+ immune-effector cells. This designed cytokine is genetically regulated by a T cell activation-responsive promoter, allowing dynamic production from chimeric antigen receptor (CAR) T cells. Like wild type IL-2, OUTSMART dIL-2 drives T cell proliferation and enhances effector function. Unlike wild type IL-2, it preferentially stimulates CD8+ T cells and Natural Killer (NK) cells, avoids T regulatory cells, and stimulates CAR-T proliferation while preserving stemness, achieving durable tumor elimination in two solid tumor animal models. These design principles can be applied to create other dynamically-regulated cytokine systems that address mechanisms of complex disease.

  • Open Access

    A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors

    by Rupesh H. Amin, Kevin G. Haworth, Howell F. Moffett, Jerry C. Chen, Lisa Park, Jason K. Yokoyama, Allan L. Wang, Leah J. Tait, Maria M. Steele, John T. Crowl, et al.

    The eradication of solid tumors by chimeric antigen receptor (CAR) T cells requires dynamic therapies capable of outlasting an immune suppressive tumor microenvironment (TME). However, biological barriers—including rapid exhaustion, poor expansion, and loss of stem-like memory—quickly neutralize these therapies 1 . Because single-technology interventions often introduce unacceptable tradeoffs between efficacy and safety, durable remission demands a paradigm where multiple engineered solutions work in concert. To holistically address these mechanisms, we rationally designed a single-vector transgene that intrinsically drives CAR T functional persistence. The platform integrates four synergistic technologies: a high-avidity mesothelin (MSLN)-targeting CAR optimized to resist shed decoy antigens, a T-cell activation-responsive promoter (OUTLAST OP1) resisting exhaustion, a CD8α-targeted designed IL-2 cytokine (OUTSMART dIL-2) driving intratumoral CAR-T expansion, and an EGFRopt 2 safety switch. In lung and ovarian cancer models, this rational integration was required to drive antigen-dependent T cell expansion and eradicate established tumors at extremely low CAR T doses. Furthermore, engineered cells established a self-renewing pool of stem-like memory T cells capable of rejecting tumor rechallenge months later. Ultimately, this work demonstrates that intrinsic T cell dysfunction and extrinsic tumor-derived barriers can be simultaneously overcome by integrating synergistic technologies.

  • Open Access

    In vivo selection of synthetic nucleocapsids for tissue targeting

    by Audrey Olshefsky, Halli Benasutti, Meilyn Sylvestre, Gabriel L. Butterfield, Gabriel J. Rocklin, Christian Richardson, Derrick R. Hicks, Marc J. Lajoie, Kefan Song, Elizabeth Leaf, et al.

    Controlling the biodistribution of protein- and nanoparticle-based therapeutic formulations remains challenging. In vivo library selection is an effective method for identifying constructs that exhibit desired distribution behavior; library variants can be selected based on their ability to localize to the tissue or compartment of interest despite complex physiological challenges. Here, we describe further development of an in vivo library selection platform based on self-assembling protein nanoparticles encapsulating their own mRNA genomes (synthetic nucleocapsids or synNCs). We tested two distinct libraries: a low-diversity library composed of synNC surface mutations (45 variants) and a high-diversity library composed of synNCs displaying miniproteins with binder-like properties (6.2 million variants). While we did not identify any variants from the low-diversity surface library that yielded therapeutically relevant changes in biodistribution, the high-diversity miniprotein display library yielded variants that shifted accumulation toward lungs or muscles in just two rounds of in vivo selection. Our approach should contribute to achieving specific tissue homing patterns and identifying targeting ligands for diseases of interest.


  • Characterizing the portability of phage-encoded homologous recombination proteins

    by Gabriel T. Filsinger, Timothy M. Wannier, Felix B. Pedersen, Isaac D. Lutz, Julie Zhang, Devon A. Stork, Anik Debnath, Kevin Gozzi, Helene Kuchwara, Verena Volf, et al.

    Efficient genome editing methods are essential for biotechnology and fundamental research. Homologous recombination (HR) is the most versatile method of genome editing, but techniques that rely on host RecA-mediated pathways are inefficient and laborious. Phage-encoded single-stranded DNA annealing proteins (SSAPs) improve HR 1,000-fold above endogenous levels. However, they are not broadly functional. Using Escherichia coli, Lactococcus lactis, Mycobacterium smegmatis, Lactobacillus rhamnosus and Caulobacter crescentus, we investigated the limited portability of SSAPs. We find that these proteins specifically recognize the C-terminal tail of the host’s single-stranded DNA-binding protein (SSB) and are portable between species only if compatibility with this host domain is maintained. Furthermore, we find that co-expressing SSAPs with SSBs can significantly improve genome editing efficiency, in some species enabling SSAP functionality even without host compatibility. Finally, we find that high-efficiency HR far surpasses the mutational capacity of commonly used random mutagenesis methods, generating exceptional phenotypes that are inaccessible through sequential nucleotide conversions.


  • Designed protein logic to target cells with precise combinations of surface antigens

    by Marc J. Lajoie, Scott E. Boyken, Alexander I. Salter, Jilliane Bruffey, Anusha Rajan, Robert A. Langan, Audrey Olshefsky, Vishaka Muhunthan, Matthew J. Bick, Mesfin Gewe, et al.

    Logic at the cell surface: A major challenge in medical interventions is to target only diseased cells. Although there are biomarkers characteristic of certain cancers, for example, it is unlikely that a single marker can specify a particular cell type. Lajoie et al. addressed this problem by designing protein switches called Co-LOCKR that bind to antigens on the cell surface and activate through a conformational change only when there is a precise combination of antigens. They designed switches that can perform AND, OR, and NOT logic. On the path toward applying this technology, they used Co-LOCKR to direct chimeric antigen receptor T cells to tumor cells expressing specific antigens. Science , this issue p. 1637


  • Improved bacterial recombineering by parallelized protein discovery

    by Timothy M. Wannier, Akos Nyerges, Helene M. Kuchwara, Márton Czikkely, Dávid Balogh, Gabriel T. Filsinger, Nathaniel C. Borders, Christopher J. Gregg, Marc J. Lajoie, Xavier Rios, et al.

    Significance: Bacterial recombineering allows researchers to interrogate microbes by modifying their genomic DNA. Improvements to the efficiency of recombineering have allowed many simultaneous edits to be made at once. Here we describe "serial enrichment for efficient recombineering" (SEER), a method for identifying efficient single-stranded DNA-annealing proteins (SSAPs) in a microbe of interest. We use SEER to identify two SSAPs: 1) CspRecT doubles editing efficiency over Redβ, the state-of-the-art in Escherichia coli recombineering; and 2) PapRecT achieves high efficiency in Pseudomonas aeruginosa , a widely studied human pathogen. We show that these SSAPs work effectively across a broad range of Gammaproteobacteria, demonstrate vastly improved performance in multiplex applications, and provide broad host-range plasmid resources.


  • Open Access

    Improved bacterial recombineering by parallelized protein discovery

    by Timothy M. Wannier, Akos Nyerges, Helene M. Kuchwara, Márton Czikkely, Dávid Balogh, Gabriel T. Filsinger, Nathaniel C. Borders, Christopher J. Gregg, Marc J. Lajoie, Xavier Rios, et al.

    Exploiting bacteriophage-derived homologous recombination processes has enabled precise, multiplex editing of microbial genomes and the construction of billions of customized genetic variants in a single day. The techniques that enable this, Multiplex Automated Genome Engineering (MAGE) and directed evolution with random genomic mutations (DIvERGE), are however currently limited to a handful of microorganisms for which single-stranded DNA-annealing proteins (SSAPs) that promote efficient recombineering have been identified. Thus, to enable genome-scale engineering in new hosts, highly efficient SSAPs must first be found. Here we introduce a high-throughput method for SSAP discovery that we call Serial Enrichment for Efficient Recombineering (SEER). By performing SEER in E. coli to screen hundreds of putative SSAPs, we identify highly active variants PapRecT and CspRecT. CspRecT increases the efficiency of single-locus editing to as high as 50% and improves multiplex editing by 5 to 10-fold in E. coli , while PapRecT enables efficient recombineering in Pseudomonas aeruginosa , a concerning human pathogen. CspRecT and PapRecT are also active in other, clinically and biotechnologically relevant enterobacteria. We envision that the deployment of SEER in new species will pave the way toward pooled interrogation of genotype-to-phenotype relationships in previously intractable bacteria.


  • Open Access

    Millstone: software for multiplex microbial genome analysis and engineering

    by Daniel B. Goodman, Gleb Kuznetsov, Marc J. Lajoie, Brian W. Ahern, Michael G. Napolitano, Kevin Y. Chen, Changping Chen, George M. Church

    Inexpensive DNA sequencing and advances in genome editing have made computational analysis a major rate-limiting step in adaptive laboratory evolution and microbial genome engineering. We describe Millstone, a web-based platform that automates genotype comparison and visualization for projects with up to hundreds of genomic samples. To enable iterative genome engineering, Millstone allows users to design oligonucleotide libraries and create successive versions of reference genomes. Millstone is open source and easily deployable to a cloud platform, local cluster, or desktop, making it a scalable solution for any lab.


  • An orthogonalized platform for genetic code expansion in both bacteria and eukaryotes

    by James S Italia, Partha Sarathi Addy, Chester J J Wrobel, Lisa A Crawford, Marc J Lajoie, Yunan Zheng, Abhishek Chatterjee

    In this study, we demonstrate the feasibility of expanding the genetic code of Escherichia coli using its own tryptophanyl-tRNA synthetase and tRNA (TrpRS-tRNATrp) pair. This was made possible by first functionally replacing this endogenous pair with an E. coli-optimized counterpart from Saccharomyces cerevisiae, and then reintroducing the liberated E. coli TrpRS-tRNATrp pair into the resulting strain as a nonsense suppressor, which was then followed by its directed evolution to genetically encode several new unnatural amino acids (UAAs). These engineered TrpRS-tRNATrp variants were also able to drive efficient UAA mutagenesis in mammalian cells. Since bacteria-derived aminoacyl-tRNA synthetase (aaRS)-tRNA pairs are typically orthogonal in eukaryotes, our work provides a general strategy to develop additional aaRS-tRNA pairs that can be used for UAA mutagenesis of proteins expressed in both E. coli and eukaryotes.